➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Baxter
McKesson
Mallinckrodt
McKinsey

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,539,214


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,539,214
Title:Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof.
Inventor(s): Plachetka; John R. (Chapel Hill, NC)
Assignee: Pozen Inc. (Chapel Hill, NC)
Application Number:14/367,972
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,539,214
Patent Claims: 1. A method for delivering a pharmaceutical composition to a patient in need thereof, comprising administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof, wherein said omeprazole, or pharmaceutically acceptable salt thereof, wherein said omeprazole, or pharmaceutically acceptable salt thereof is an immediate release omeprazole, or pharmaceutically acceptable salt thereof and is released from said unit dose form at a pH of from about 0 or greater to target a mean time at which intragastric pH remains at about 4.0 or greater for about a 24 hour period after reaching steady state of at least about 50% and wherein one unit dose form is administered to target: i) a pharmacokinetic (pk) profile for acetylsalicylic acid where: a) the dose has a acetylsalicylic acid mean C.sub.max of about 2.0 to about 3.0 .mu.g/mL and a median time to maximum concentration (T.sub.max) of from about 3.0 to about 3.5 hours, and/or b) the dose has a salicylic acid mean C.sub.max of about 15 to about 16.5 .mu.g/mL and a median time to maximum concentration (T.sub.max) of from about 3.0 to about 3.5 hours, ii) a pharmacokinetic (pk) profile for omeprazole where the dose has a mean area under the plasma concentration-time curve from time zero when the dose is administered to about 12 hours after the dose is administered (AUC.sub.0-12) of about 0.8 to about 2.5 hr*.mu.g/mL.

2. The method according to claim 1, wherein the pk profile for acetylsalicylic acid has a mean acetylsalicylic acid C.sub.max of at least 2.36 .mu.g/ml and a mean salicylic acid C.sub.max of at least 15.3 .mu.g/ml.

3. The method according to claim 1, wherein the pk profile for acetylsalicylic acid has a mean acetylsalicylic acid C.sub.max of about 2.91 .mu.g/ml and a mean salicylic acid C.sub.max of at least 16.2 .mu.g/ml.

4. The method according to claim 3, wherein the % coefficient of variation for acetylsalicylic acid is about 54%, and the coefficient of variation for salicylic acid is about 29%.

5. The method according to claim 1, wherein the omeprazole mean area under the plasma concentration-time curve from time zero when the dose is administered to about 12 hours after the dose is administered (AUC.sub.0-12) is about 2.174 hr*.mu.g/mL.

6. The method according to claim 5, wherein the % coefficient of variation for the omeprazole mean area under the plasma concentration-time curve from time zero when the dose is administered to about 12 hours after the dose is administered (AUC.sub.0-12) is about 88%.

7. The method according to claim 1, wherein the omeprazole mean area under the plasma concentration-time curve from time zero when the dose is administered to about 24 hours after the dose is administered (AUC.sub.0-24) of about 2.187 hr*.mu.g/mL.

8. The method according to claim 7, wherein the % coefficient of variation for the omeprazole mean area under the plasma concentration-time curve from time zero when the dose is administered to about 24 hours after the dose is administered (AUC.sub.0-24) is about 88%.

9. The method according to claim 1, wherein said pharmaceutical composition in unit dose form comprises about 325 mg of said acetylsalicylic acid and about 40 mg of said omeprazole.

10. The method according to claim 1, wherein said unit dose form is administered for a period of at least about 7 days.

11. The method according to claim 1, wherein said unit dose form is administered for a period of at least about 14 days.

12. The method according to claim 1, wherein said unit dose form is a multilayer tablet comprising at least one core and at least a first layer and a second layer, wherein: i) said core comprises acetylsalicylic acid, or pharmaceutically acceptable salt thereof; ii) said first layer is a coating that at least begins to dissolve when the pH of the surrounding medium is about 3.5 or greater; and iii) said second layer comprises omeprazole, wherein said omeprazole is released at a pH of from about 0 or greater.

13. The method according to claim 12, wherein said omeprazole is released at a pH of from about 0 to about 2.

14. The method according to claim 1, wherein said patient in need thereof is being treated for a disease or disorder selected from pain and inflammation.

15. The method according to claim 1, wherein said patient in need thereof is being treated for cardiovascular disease, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, or a combination thereof.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Medtronic
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.